amrinone has been researched along with Chronic Illness in 16 studies
Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.
amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A placebo-controlled study was employed to evaluate the effects of oral amrinone in patients with congestive heart failure." | 9.05 | Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. ( Benotti, JR; DiBianco, R; Leier, CV; Shabetai, R; Silverman, BD, 1984) |
| "To determine the hemodynamic and clinical effects of long-term positive inotropic stimulation on the myocardium, we treated 31 patients with severe chronic heart failure with oral amrinone (600 mg daily) and performed invasive hemodynamic studies during short- and long-term treatment with the drug." | 7.67 | Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Although amrinone produces acute hemodynamic improvement in patients with severe chronic congestive heart failure (CHF), it has not produced clinical benefits in long-term controlled trials." | 7.67 | Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "The efficacy and safety of oral amrinone were examined in 17 patients with moderately severe to severe heart failure that was refractory to standard medical therapy and vasodilators." | 7.67 | Amrinone in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Sutton, MS; Weber, KT; Wilson, H, 1984) |
| "The pharmacokinetics of amrinone and its relationship to ventricular function were assessed in 15 patients with chronic cardiac failure following the administration of a single 100 mg oral dose." | 7.67 | Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ( Andrews, V; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1987) |
| "Amrinone, a new inotropic agent, was used to treat 24 patients with chronic congestive heart failure who were classified as clinically stable and who were in New York Heart Association's classes II and III." | 7.67 | Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure. ( Gerber, L; Merrill, AJ; Silverman, BD, 1985) |
| "Amrinone, a new inotropic agent, has been shown to be beneficial in patients with congestive heart failure." | 7.66 | Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. ( Frishman, WH; Klein, NA; LeJemtel, TH; Siskind, SJ; Sonnenblick, EH, 1981) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 6.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "A placebo-controlled study was employed to evaluate the effects of oral amrinone in patients with congestive heart failure." | 5.05 | Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. ( Benotti, JR; DiBianco, R; Leier, CV; Shabetai, R; Silverman, BD, 1984) |
| "The authors describe the results obtained treating with amrinone for 48 hours 11 patients with acute heart failure." | 3.68 | [Efficacy and safety of amrinone in the treatment of heart insufficiency in intensive care]. ( Agrò, C; Costa, P; Gulotta, G; Papa, G; Piazza, F; Ronga, F; Sansone, A; Sparacia, B, 1992) |
| "To determine the hemodynamic and clinical effects of long-term positive inotropic stimulation on the myocardium, we treated 31 patients with severe chronic heart failure with oral amrinone (600 mg daily) and performed invasive hemodynamic studies during short- and long-term treatment with the drug." | 3.67 | Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "Although amrinone produces acute hemodynamic improvement in patients with severe chronic congestive heart failure (CHF), it has not produced clinical benefits in long-term controlled trials." | 3.67 | Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure. ( Medina, N; Packer, M; Yushak, M, 1984) |
| "The efficacy and safety of oral amrinone were examined in 17 patients with moderately severe to severe heart failure that was refractory to standard medical therapy and vasodilators." | 3.67 | Amrinone in the treatment of chronic cardiac failure. ( Andrews, V; Janicki, JS; Likoff, MJ; Rocci, ML; Sutton, MS; Weber, KT; Wilson, H, 1984) |
| "The pharmacokinetics of amrinone and its relationship to ventricular function were assessed in 15 patients with chronic cardiac failure following the administration of a single 100 mg oral dose." | 3.67 | Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology. ( Andrews, V; Likoff, MJ; Rocci, ML; Weber, KT; Wilson, H, 1987) |
| "Amrinone, a new inotropic agent, was used to treat 24 patients with chronic congestive heart failure who were classified as clinically stable and who were in New York Heart Association's classes II and III." | 3.67 | Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure. ( Gerber, L; Merrill, AJ; Silverman, BD, 1985) |
| "Amrinone, a new inotropic agent, has been shown to be beneficial in patients with congestive heart failure." | 3.66 | Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. ( Frishman, WH; Klein, NA; LeJemtel, TH; Siskind, SJ; Sonnenblick, EH, 1981) |
| "Oral amrinone or pirbuterol were given in random order to each of 13 patients, on successive days, and oral isosorbide dinitrate was added after two-and-a-half hours." | 2.65 | Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. ( Bayliss, J; Canepa-Anson, R; Norell, M; Poole-Wilson, PA; Reuben, SR; Sutton, GC, 1983) |
| "Amrinone (A) has been administered to 10 patients with low postoperative cardiac output as unique inotropic therapy and to 34 patients in severe cardiogenic shock, despite optimal treatment." | 1.27 | New inotropic-vasodilating drugs in acute and chronic heart failure. ( Goenen, MJ, 1986) |
| "Chronic congestive heart failure is a frequently occurring disease associated with an impaired quality of life and significant mortality rate." | 1.27 | Chronic congestive heart failure. Where have we been? Where are we heading? ( Applefeld, MM, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (87.50) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (6.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Endoh, M | 1 |
| Bijak, A | 1 |
| Czołpiński, T | 1 |
| DiBianco, R | 1 |
| Shabetai, R | 1 |
| Silverman, BD | 2 |
| Leier, CV | 1 |
| Benotti, JR | 1 |
| Packer, M | 2 |
| Medina, N | 2 |
| Yushak, M | 2 |
| Likoff, MJ | 3 |
| Weber, KT | 5 |
| Andrews, V | 4 |
| Janicki, JS | 4 |
| Sutton, MS | 1 |
| Wilson, H | 2 |
| Rocci, ML | 2 |
| Bayliss, J | 1 |
| Norell, M | 1 |
| Canepa-Anson, R | 1 |
| Reuben, SR | 1 |
| Poole-Wilson, PA | 1 |
| Sutton, GC | 1 |
| Wilson, JR | 1 |
| Fishman, AP | 1 |
| Klein, NA | 1 |
| Siskind, SJ | 1 |
| Frishman, WH | 1 |
| Sonnenblick, EH | 1 |
| LeJemtel, TH | 1 |
| Costa, P | 1 |
| Agrò, C | 1 |
| Gulotta, G | 1 |
| Papa, G | 1 |
| Piazza, F | 1 |
| Ronga, F | 1 |
| Sparacia, B | 1 |
| Sansone, A | 1 |
| Maskin, CS | 1 |
| Goenen, MJ | 1 |
| Applefeld, MM | 1 |
| Merrill, AJ | 1 |
| Gerber, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children[NCT02728128] | 53 participants (Actual) | Observational | 2016-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for amrinone and Chronic Illness
| Article | Year |
|---|---|
[New drugs with positive inotropic action].
Topics: Adrenergic beta-Agonists; Albuterol; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; | 1982 |
Effects of new inotropic agents on exercise performance.
Topics: Adrenergic beta-Agonists; Aminopyridines; Amrinone; Cardiac Output; Cardiotonic Agents; Chronic Dise | 1986 |
2 trials available for amrinone and Chronic Illness
| Article | Year |
|---|---|
Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic | 1984 |
Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Drug Therapy, Combinatio | 1983 |
12 other studies available for amrinone and Chronic Illness
| Article | Year |
|---|---|
Amrinone, forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy.
Topics: Amrinone; Animals; Calcium Signaling; Cardiotonic Agents; Chronic Disease; Disease Models, Animal; D | 2013 |
Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Cardiac Output; Chronic Disease; Female; Heart Failure; Human | 1984 |
Amrinone: a promising new cardiotonic agent in the treatment of chronic cardiac failure.
Topics: Activities of Daily Living; Aminopyridines; Amrinone; Animals; Cardiotonic Agents; Cats; Chronic Dis | 1983 |
Failure of low doses of amrinone to produce sustained hemodynamic improvement in patients with severe chronic congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Blood Pressure; Cardiotonic Agents; Chronic Disease; Dose-Res | 1984 |
Amrinone in the treatment of chronic cardiac failure.
Topics: Aged; Aminopyridines; Amrinone; Cardiotonic Agents; Chronic Disease; Double-Blind Method; Drug Evalu | 1984 |
Amrinone and exercise performance in patients with chronic heart failure.
Topics: Aminopyridines; Amrinone; Chronic Disease; Exercise Test; Female; Heart Failure; Hemodynamics; Human | 1981 |
Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Aminopyridines; Amrinone; Cardiac Output; Catecholamines; Chronic Disease; | 1981 |
[Efficacy and safety of amrinone in the treatment of heart insufficiency in intensive care].
Topics: Acute Disease; Aged; Aged, 80 and over; Amrinone; Chronic Disease; Critical Care; Female; Heart Fail | 1992 |
Pharmacokinetics and hemodynamics of amrinone in patients with chronic cardiac failure of diverse etiology.
Topics: Acetylation; Amrinone; Cardiac Output; Chronic Disease; Half-Life; Heart Failure; Hemodynamics; Huma | 1987 |
New inotropic-vasodilating drugs in acute and chronic heart failure.
Topics: Acute Disease; Administration, Oral; Amrinone; Cardiotonic Agents; Chronic Disease; Heart Failure; H | 1986 |
Chronic congestive heart failure. Where have we been? Where are we heading?
Topics: Aminopyridines; Amrinone; Biopsy; Calcium Channel Blockers; Cardiology; Chronic Disease; Digitalis; | 1986 |
Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure.
Topics: Adult; Aged; Aminopyridines; Amrinone; Arrhythmias, Cardiac; Cardiotonic Agents; Chronic Disease; El | 1985 |